Global Digital Polymerase Chain Reaction (PCR) Market – Industry Trends and Forecast to 2031

Digital Polymerase Chain Reaction (PCR) Market Analysis and Size

The increase in diabetic patients has propelled the demand for precise diagnostic tools, leading to advancements in the digital polymerase chain reaction (PCR) market. Digital PCR technology offers highly sensitive and accurate detection of genetic markers associated with diabetes, aiding in early diagnosis and personalized treatment approaches. Its ability to detect rare mutations and quantify target DNA with high precision makes it invaluable in monitoring disease progression and evaluating treatment efficacy in diabetic patients. Moreover, digital PCR's automation capabilities streamline testing processes, enhancing efficiency in clinical laboratories and enabling rapid turnaround times for patient results.

Global digital polymerase chain reaction (PCR) market size was valued at USD 6.83 billion in 2023 and is projected to reach USD 15.86 billion by 2031, with a CAGR of 11.1% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Market Definition

Digital PCR quantifies and amplifies nucleic acids such as DNA, cDNA, or RNA by partitioning samples into numerous small reactions and detecting positive ones. It offers superior sensitivity and accuracy compared to traditional PCR methods, making it ideal for applications demanding precise detection of minimal nucleic acid inputs or nuanced target amount distinctions. Its efficacy shines in rare sequence detection, copy number variation (CNV) analysis, and gene expression profiling of low-abundance targets.

Digital Polymerase Chain Reaction (PCR) Market Dynamics

Drivers

• Rise in Availability of Digital PCR Diagnostics Leads to Increased Infectious Disease Monitoring

Digital PCR offers unparalleled sensitivity, precision, and accuracy in detecting and quantifying nucleic acids, making it indispensable in various diagnostic applications. Its ability to detect rare mutations, quantify viral load, and assess gene expression levels with high sensitivity has made it a preferred choice in clinical diagnostics, infectious disease monitoring, and oncology. Additionally, advancements such as customized assay design services and integrated systems have further expanded its utility, driving market adoption. As healthcare systems increasingly prioritize precision medicine and personalized diagnostics, the demand for digital PCR technologies is expected to continue rising, fostering market expansion and innovation.

• Growing Research and Development Activities Enhances Speed of Digital PCR Systems

Innovations in product development, driven by R&D efforts, continuously enhance the efficiency, accuracy, and speed of digital PCR systems. These advancements cater to the increasing demand for precise nucleic acid quantification in various fields such as biotechnology, healthcare, and diagnostics. R&D initiatives focus on improving key aspects such as multiplexing capabilities, assay sensitivity, and automation, enabling researchers to address complex biological questions with greater precision and throughput. Consequently, the market witnesses sustained expansion as organizations invest in R&D to stay competitive and meet evolving customer needs for advanced molecular analysis technologies.

Opportunities

• High Prevalence of Cancer Leads to the Adoption of Digital PCR Technology

Digital PCR offers unparalleled sensitivity and precision in detecting and quantifying nucleic acids, making it particularly valuable for cancer diagnosis, monitoring, and treatment. Its ability to detect rare mutations or trace amounts of tumor DNA in bodily fluids enables early detection and personalized therapy approaches. Moreover, as cancer incidence rates continue to rise globally, there is a growing demand for robust molecular diagnostic tools such as digital PCR to support oncology research and clinical practice. This trend has fueled investments in digital PCR technology, driving market growth and innovation in cancer diagnostics and therapeutics.

In 2021, as highlighted by the American Cancer Society's statistics, accentuates the critical role of advanced molecular diagnostics such as Digital PCR in cancer management. With nearly 1.9 million new cases of cancer in the U.S. alone in 2021, there is an urgent need for sensitive and precise diagnostic tools to enable early detection and personalized treatment strategies. Digital PCR's unparalleled sensitivity to detect rare mutations and trace tumor DNA in bodily fluids positions it as a pivotal technology in oncology research and clinical practice, aiding in improving patient outcomes and reducing the global cancer burden.

• Rising Demand for Precision Medicine in the Management of Chronic Disorders

Digital PCR offers unparalleled accuracy and sensitivity in quantifying nucleic acids, making it an ideal tool for the precise diagnosis, monitoring, and personalized treatment of chronic conditions. Its ability to detect rare genetic mutations and variations with high precision allows for tailored therapeutic approaches, enhancing patient outcomes and reducing healthcare costs associated with trial-and-error treatments. Furthermore, the expanding applications of digital PCR in companion diagnostics and pharmacogenomics further bolster its potential in driving advancements in precision medicine.

Amerigo Scientific's expansion of its cell culture portfolio in August 2021 highlights the growing market opportunity in 3D cell culture. It introduces a new 3D cell culture system tailored for scientific applications such as drug discovery, medicine, nanomaterial evaluation, and basic life science research, Amerigo Scientific is capitalizing on the increasing demand for advanced cell culture technologies. This move underscores the industry's momentum towards leveraging innovative solutions to enhance research efficacy and address complex biological challenges.

Restraints/Challenges

• High Cost of Implementation Limits the Adoption of 3D Cell Culture Techniques

As devices become increasingly sophisticated and diverse in their functionalities, conventional PCR systems may struggle to accommodate their unique requirements effectively. This limitation can hinder the ability of PCR technologies to accurately detect and quantify nucleic acids in complex devices, potentially leading to suboptimal results and reduced utility in certain applications.

• Shortage of Skilled Professionals Leads to Potential Errors

Without adequate expertise, users may encounter difficulties in operating complex PCR systems, leading to potential errors in experimental setup, data interpretation, and result analysis. These errors can compromise the accuracy and reliability of nucleic acid quantification, undermining the trust in digital PCR technology. Additionally, the shortage hampers the adoption of advanced PCR techniques, limiting the market growth as organizations struggle to fully leverage the capabilities of digital PCR platforms for research, diagnostics, and therapeutics.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In July 2023, QIAGEN collaborates with Niba Labs to enhance its digital PCR offerings for the biopharma sector, providing tailored dPCR assay design services. This collaboration leverages Niba Labs' expertise in assay development and sample testing, enabling QIAcuity customers to access custom simplex or multiplex assays for nucleic acid quantification
• In September 2021, ThermoFisher Scientific launches a fully integrated digital PCR system, promising precise and consistent results in just 90 minutes. This system represents a significant advancement in PCR technology, catering to researchers' need for rapid and accurate nucleic acid analysis
• In July 2021, Stilla Technologies launches it’s sic Color Crystal Digital PCR access program, granting the industry early access to its digital PCR system equipped with six fluorescent channels. This initiative aims to accelerate research and development efforts by providing advanced PCR technology capable of high-resolution nucleic acid analysis

Digital Polymerase Chain Reaction (PCR) Market Scope

The market is segmented on the basis of product type, technology, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

Product Type

• Digital PCR Instruments
• Consumables and Reagents
• Software and Services

Technology

• Droplet Digital PCR
• Beaming Digital PCR

Application

• Clinical
• Life Science and Research
• Others

End User

• Pharmaceutical and Biotechnology Companies
• Hospitals and Clinics
• Diagnostic Laboratories
• Academic and Research Organizations
• Reference Laboratories
• Others

Distribution Channel

• Direct Tenders
• Retail Sales
• Others

Digital Polymerase Chain Reaction (PCR) Market Regional Analysis/Insights

The market is segmented into five notable segments based on product type, application, technology, end user, and distribution channel.   

The countries covered in this market report U.S., Canada, Mexico, Germany, France, Italy, Spain. U.K., Switzerland, Netherlands, Russia, Turkey, Sweden, Belgium, Poland, Norway, Finland, Denmark, Rest of Europe, Japan, China, India, South Korea, Australia, New Zealand, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, U.A.E., Egypt, Bahrain, Qatar, Oman, Saudi Arabia, Kuwait, and Rest of Middle East and Africa.   

In North America, U.S. is expected to dominate the digital PCR market, fueled by rising investments in this technology. It hold the forefront position, primarily attributed to the substantial presence of key industry players. This dominance underscores the country's robust infrastructure, technological advancements, and strategic initiatives driving the adoption of digital PCR solutions.

In Europe, Germany is expected to dominate the market due to several factors, including its strong industrial base, advanced infrastructure, and strategic geographical location. The country's robust economy and technological expertise position it as a key player in meeting the growing demand for various products and services across emerging markets within Europe. Additionally, Germany's proactive approach towards expansion initiatives and its emphasis on innovation further contribute to its anticipated dominance in the region's market landscape.

In Asia-Pacific, China is expected to dominate the market due to rising customer preferences for this technology. Factors such as the growing awareness of the benefits of digital PCR, including its higher sensitivity and accuracy, are driving adoption. Additionally, China's robust biopharmaceutical sector and investment in life sciences research contribute to the country's leading position in embracing advanced molecular diagnostic technologies such as digital PCR. This trend suggests a significant market opportunity for digital PCR manufacturers and service providers looking to expand their presence in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Digital Polymerase Chain Reaction (PCR) Market Analysis

The market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.

Some of the major players operating in the market are:

•  F. HoffmannLa Roche Ltd (Switzerland)
•  BioRad Laboratories Inc. (U.S.)
•  Merck KGaA (Germany)
•  Thermo Fisher Scientific Inc. (U.S.)
•  QIAGEN (Netherlands)
•  Eppendorf SE (Germany)
•  Sysmex Inostics Inc. (Japan)
•  Stilla (France)
•  RainSure Scientific (U.S.)
•  Accumax (India)
•  Standard BioTools (U.S.)
•  JN Medsys (Singapore)
•  VSI Electronics Pvt. Ltd (India)
•  Precigenome LLC (U.S.)

SKU-56545